title: Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
abstract: This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagnosed at endoscopy C pylori was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence of C pylori after six weeks of treatment (p less than 0.001). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylori, unlike in the cimetidine group. C pylori was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p less than 0.001).
authors: Department of Clinical Microbiology, St James's Hospital, Dublin, Ireland.
authors: H
authors: H
authors: Humphreys
authors: S
authors: S
authors: Bourke
authors: C
authors: C
authors: Dooley
authors: D
authors: D
authors: McKenna
authors: B
authors: B
authors: Power
authors: C T
authors: CT
authors: Keane
authors: E C
authors: EC
authors: Sweeney
authors: C
authors: C
authors: O'Moráin
mesh_terms: D000328:Adult; D002169:Campylobacter Infections / Q000150:complications / Q000188:drug therapy*; D002927:Cimetidine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004941:Esophagitis / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology; D011446:Prospective Studies; D011897:Random Allocation
chemical_list: D009942:Organometallic Compounds; D002927:Cimetidine; C002791:bismuth tripotassium dicitrate